Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm?
Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to become even more competitive with forthcoming entrants in Brazil, Mexico, and Argentina, such as long-acting GLP-1 receptor agonists and DPP-IV inhibitors, and the novel fixed-dose combinations of SGLT-2 inhibitors/metformin and of DPP-IV inhibitors/SGLT-2 inhibitors. Emerging therapies will likely be met with increased formulary and budgetary restrictions in these markets. As local and national governments have to bear the burden of treating a growing population with the disease, it is left to know if the treatment algorithm for T2D will advance as the treatment armamentarium evolves, or if it will stagnate even though more effective, yet more expensive therapies become available in these markets.
This Emerging Physician & Payer Forum surveys 152 endocrinologists and primary care physicians to explore the prescribing and access environment for key non-insulin treatments for T2D, with a focus on current and emerging DPP-IV inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors, and how it will evolve in these countries in the next 2-3 years. Interviewees were required to be influential in determining patient access to therapies for T2D at the institutional or regional/national level, and came from the following backgrounds:
- Brazil: Head of pharmaceutical assistance programs at São Paulo State; head of the pharmaceutical division of a major public hospital in São Paulo, consultant for the São Paulo State Department of Health and the Ministry of Health, specialist in pharmacoeconomics; director of the drug standardization committee and audit department at a major HMO; medical auditor responsible for the disease and portfolio management at a major insurance company, member of the drug standardization committee of the institution.
- Mexico: Coordinator of the National Staged Diabetes Medical Management Program at ISSSTE; endocrinologist responsible for the diabetes and obesity program at a family medicine unit from IMSS; endocrinologist KOL, director of the endocrinology department at a major private hospital in Mexico, member of the Board of Governors of Mexico State at the Mexico chapter of the American College of Physicians.
- Argentina: Medical director of management, prevention, and treatment programs from a major national obra social; chief of the endocrinology department at major hospital in Buenos Aires; member of the SADE and the ALAD; chief of the audit department at a major private hospital.
Already a Client? Log in to access this report.